Chronic rejection remains a major source of morbidity and mortality following lung transplantation. The clinical characteristics of chronic rejection involves bronchiolitis obliterans syndrome (BOS), which leads to progressive airway obstruction. Changes in intrathoracic tracheal dimensions and shape are commonly present in the setting of airway obstruction, leading to the narrowing of the intrathoracic trachea in the coronal plane with anteroposterior lengthening characteristic of the saber-sheath trachea deformity. We present a 64-year-old man who underwent left lung transplantation for idiopathic pulmonary fibrosis who later developed sabersheath trachea as a result of chronic airway obstruction due to BOS. Chronic Respiratory Disease 2009; 6: 49-52
Introduction
Despite improvements in surgical techniques, lung preservation, immunosuppression, and management of ischemia/reperfusion injury and infections, chronic allograft dysfunction or rejection remains to be the major obstacle that threatens both the quality of life and long-term survival of the lung transplant recipients. 1 Bronchiolitis obliterans syndrome (BOS) is the clinical counterpart of obliterative bronchiolitis (OB), which results in progressive narrowing of bronchiolar lumens and airflow obstruction, and is the manifestation of chronic allograft rejection which affects up to 50-60% of patients who survive 5 years after transplantation and accounts for >30% of all deaths occurring after the third postoperative year. 1 The histological findings of OB are characterized by an inflammatory process that constricts and ultimately obliterates the small airways. 2 The diagnosis of BOS is usually made by clinical, physiological, and radiographic parameters. The current classification of BOS is based on changes in forced expiratory volume in one second (FEV 1 ) with the maximum post-transplant FEV 1 , being assigned a 100% predicted value (the mean of the two best postoperative FEV 1 values with at least three weeks between the measurements) and a reduction in the mean forced expiratory flow during the middle half of the forced vital capacity (FEF 25-75% ), which is used as an early marker for BOS. 3 Saber-sheath trachea, which is a rare phenomenon and is only described in patients with chronic obstructive pulmonary disease (COPD), has never been reported in BOS due to chronic lung allograft rejection. Intrathoracic tracheal dimensions and shape changes occur in the setting of saber-sheath trachea with the radiographic definition being a tracheal index (TI) or the ratio of the coronal to the sagittal diameter measured 1 cm above the aortic arch less than 0.67. 4 Saber-sheath trachea (TI < 2/3) is commonly used as a specific radiographic diagnostic parameter for the diagnosis of COPD with a specificity of 92.9% but a sensitivity of 39.1%. 4 This case illustrates the development of a saber-sheath trachea in a patient with BOS after single left lung transplantation.
Case report
A 64-year-old male, who underwent left single lung transplantation two years earlier for advanced idiopathic pulmonary fibrosis (IPF) diagnosed by open lung biopsy with histological examination confirmation by the Mayo Clinic, presented with productive cough and dyspnea with activity. His pulmonary function testing prior to the transplant showed a restrictive process with forced vital capacity (FVC) 3.81 L (65% predicted), FEV 1 3.31 L (68% predicted), and FEV 1 /FVC ratio 87% with a moderately reduced total lung capacity. The left lung transplantation was performed without complications with improved pulmonary function testing at his two month follow-up, FVC 4.92 L (84% predicted), FEV 1 4.14 L (85% predicted), and FEV 1 / FVC ratio 84%. During his pre-transplant course, his pulmonary function testing never identified airway obstruction. His clinical course later during his first year post-transplant was complicated by three episodes of acute A2B0 lung graft rejection, requiring high-dose intravenous corticosteroids with resolution histologically after treatment.
Eighteen months after lung transplantation, his pulmonary function slowly deteriorated with the development of airway obstruction, consistent with BOS. Over the next eight months, he developed a chronic, non-productive cough and mild dyspnea with exertion. His pulmonary function showed moderate airway obstruction, FVC 4.29 L (73%), FEV 1 2.13 L (44%), and FEV 1 /FVC ratio 50%, and the flow volume curve illustrated a central airway obstruction (Figure 1) . A chest x-ray ( Figure 2 ) showed fibrotic disease in the right native lung consistent with IPF and hyperinflation of the left allograft with slight tortuosity of the trachea. Bronchoscopy was performed and showed a continuous horseshoe arch morphology of the trachea (Figure 3) , which was not present on previous bronchoscopies. The remaining bronchoscopic evaluation identified no abnormalities in the right lung and a patent left allograft anastomosis. Bronchoalveolar lavage performed in the lingula identified no microbes, and transbronchial biopsies showed no rejection histologically. Figure 4 illustrates a close-up view of the computed tomography (CT) scan of the chest confirming saber-sheath deformity with a TI of 0.6. Airway clearance was instituted with an Acapella™ device (Smiths Medical, London, UK), and his symptoms improved. His clinical symptoms still continue to be closely monitored. 
Discussion
The clinical presentation and progression of BOS after lung transplantation was described by Nathan, et al. when they retrospectively analyzed serial spirometry of 15 single lung transplant patients with BOS, all subjects fulfilling criteria for BOS and 11 of the 15 subjects having histologically documented BOS. 5 Based on serial FEV 1 analysis, three patterns of presentation and progression of BOS were identified with the first pattern (n = 6) characterized by a rapid onset and a relentless progressive course; the second pattern (n = 5) characterized by a similar rapid onset and initial rapid decline, but was followed by stabilization in lung function; and the third pattern (n = 4) characterized by an insidious onset and course. 5 The narrowing of the intrathoracic trachea in the coronal plane with anteroposterior lengthening is characteristic of the saber-sheath trachea deformity. 6 This structural disorder is primarily associated with COPD and occurs in relation to chronic bronchitis. 6 Lechner investigated a group of 90 men and women with pulmonary function indicative of severe COPD demonstrating that patients with chronic cough and chronic bronchitis exhibited a tendency to intrathoracic coronal narrowing and sagittal widening consistent with sabersheath deformity. 7 In 1978, Greene established this correlation with clinical COPD when he reported 60 male patients with marked coronal narrowing of the intrathoracic trachea (saber-sheath configuration) with 57 (95%) having clinical evidence of COPD compared to 18% in the control group. 8 Trigaux, et al. described saber-sheath trachea as a phenomena of hyperinflation in a series of 20 patients with a saber-sheath trachea on CT scan (TI ≤ 0.66) and a group of 20 control COPD patients without sabersheath trachea (TI ≥ 0.70) when they assessed standard radiographic indices of COPD, sternum-spine distance and three functional tests of COPD: FEV 1 , carbon monoxide diffusing lung capacity, and functional residual capacity (FRC). 9 A significant difference was found between the two groups regarding FRC and sternum-spine distance with TI significantly correlating with FRC values and sternumspine distance. 9
Conclusions
An interesting point in this case is the different disease processes in each lung, fibrosis in the native lung and BOS in the allograft. Saber-sheath trachea is a rare phenomenon that is well-described in patients with COPD; however, this case illustrates its occurrence due to chronic airway obstruction resulting from BOS in a lung transplant recipient. Tracheal abnormalities can contribute to worsening of clinical symptoms in patients with chronic respiratory conditions, thus saber-sheath trachea should be considered in patients with BOS and declining clinical scenarios. Therapy is limited for saber-sheath trachea, but good airway clearance commonly leads to improved symptoms as in this particular case. Surgical treatment is an option for refractory cases.
